Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
14.84
-0.22 (-1.46%)
Aug 27, 2026, 10:00 AM EDT - Market open
Adlai Nortye Earnings Call Transcripts
Fiscal Year 2026
-
Two RAS-targeted programs are advancing, with AN9025 in phase I and AN4035 ADC entering clinical studies in 2024. Intermittent dosing may widen the therapeutic window, and the ADC platform enables selective tumor targeting and rational combinations, especially in colorectal cancer.